{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:09:18Z","timestamp":1792001358378,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["WO 2020\/074690"],"award-info":[{"award-number":["WO 2020\/074690"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jhepr.2023.100713","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T13:08:28Z","timestamp":1677244108000},"page":"100713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy"],"prefix":"10.1016","volume":"5","author":[{"given":"Nicholas D.","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Odriozola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ros-Ga\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garc\u00eda-Porrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josepmaria","family":"Argemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Combal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi K.","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gonz\u00e1lez-Aseguinolaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100713_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.95.1.282","article-title":"Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis","volume":"95","author":"de Vree","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhepr.2023.100713_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-4-1","article-title":"Progressive familial intrahepatic cholestasis","volume":"4","author":"Davit-Spraul","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhepr.2023.100713_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1388-1981(00)00053-6","article-title":"ABC transporters in lipid transport","volume":"1486","author":"Borst","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhepr.2023.100713_bib4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/gast.2001.23984","article-title":"The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood","volume":"120","author":"Jacquemin","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100713_bib5","article-title":"Novel vectors and approaches for gene therapy in liver diseases","volume":"3","author":"Maestro","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2023.100713_bib6","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jhep.2020.12.010","article-title":"Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4-\/- mouse model of PFIC3","volume":"74","author":"Wei","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100713_bib7","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.30773","article-title":"Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy","volume":"70","author":"Siew","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100713_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2019.03.021","article-title":"Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice","volume":"71","author":"Aronson","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100713_bib9","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41467-019-13614-3","article-title":"Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model","volume":"10","author":"Weber","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2023.100713_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","author":"Smit","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2023.100713_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.20022","article-title":"Spontaneous cholecysto- and hepatolithiasis in Mdr2-\/- mice: a model for\u00a0low phospholipid-associated cholelithiasis","volume":"39","author":"Lammert","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100713_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2005.06.025","article-title":"Mdr2 (Abcb4)-\/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes","volume":"43","author":"Popov","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100713_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/mt.2009.88","article-title":"AAV2\/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spfash mice","volume":"17","author":"Cunningham","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/hum.2011.183","article-title":"Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector","volume":"23","author":"Wang","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nbt1073","article-title":"Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart","volume":"23","author":"Wang","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhepr.2023.100713_bib17","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2023.100713_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2023.100713_bib19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5ch and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","article-title":"Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice","volume":"13","author":"Rivi\u00e8re","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14712598.2021.1865303","article-title":"Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy","volume":"21","author":"Rodr\u00edguez-M\u00e1rquez","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib22","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1002\/cti2.1375","article-title":"Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies","volume":"11","author":"Ros-Ga\u00f1\u00e1n","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jhepr.2023.100713_bib23","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","article-title":"Immunoadsorption enables successful rAAV5-mediated repeated hepatic\u00a0gene delivery in nonhuman primates","volume":"3","author":"Salas","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jhepr.2023.100713_bib24","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A\u00a010 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2023.100713_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2023.100713_bib27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jhepr.2023.100713_bib28","doi-asserted-by":"crossref","first-page":"E733","DOI":"10.1073\/pnas.1717063115","article-title":"Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity","volume":"115","author":"Mazor","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhepr.2023.100713_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhepr.2023.100713_bib30","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2023.100713_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omtm.2021.06.015","article-title":"ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia","volume":"22","author":"Ilyinskii","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhepr.2023.100713_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cellimm.2015.11.004","article-title":"Tolerogenic nanoparticles to induce immunologic tolerance: prevention and reversal of FVIII inhibitor formation","volume":"301","author":"Zhang","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jhepr.2023.100713_bib33","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific\u00a0immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhepr.2023.100713_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637469","article-title":"Enhancement of the tolerogenic phenotype in the liver by ImmTOR nanoparticles","volume":"12","author":"Ilyinskii","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2023.100713_bib35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","article-title":"Development of ImmTOR tolerogenic nanoparticles for the\u00a0mitigation of anti-drug antibodies","volume":"11","author":"Kishimoto","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2023.100713_bib36","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1073\/pnas.0908867107","article-title":"Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks","volume":"107","author":"Barash","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhepr.2023.100713_bib37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","article-title":"Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects","volume":"40","author":"Baruteau","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jhepr.2023.100713_bib38","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: from gene data mining to disease genome sequence analysis","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protocol Bioinform"},{"key":"10.1016\/j.jhepr.2023.100713_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cels.2022.05.001","article-title":"Diploid hepatocytes drive physiological liver renewal in adult humans","volume":"13","author":"Heinke","year":"2022","journal-title":"Cell Syst"},{"key":"10.1016\/j.jhepr.2023.100713_bib40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2023.100713_bib41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.mt.6300334","article-title":"Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver","volume":"16","author":"Murphy","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib42","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1053\/gast.2000.20222","article-title":"Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis","volume":"119","author":"de Vree","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100713_bib43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jhep.2021.09.033","article-title":"Comment on \u201cSynthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4-\/- mouse model of PFIC3\u201d","volume":"76","author":"Weber","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100713_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612747","article-title":"Optimize prime\/boost vaccine strategies: trained immunity as a new player in the game","volume":"12","author":"Palgen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2023.100713_bib45","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2023.100713_bib46","series-title":"The GeneCards Suite Chapter, Practical Guide to Life Science Databases","first-page":"27","author":"Safran","year":"2022"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:06:49Z","timestamp":1778904409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2589555923000447"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100713","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100713"}}